ATLANTA,
GA – 
(NewMediaWire) – February 19, 2024 – Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, announced today that its Chairman and CEO, David
Dodd, will present at the 2024 BIO CEO & Investor Conference, taking place
in-person in New York, NY on February 26-27, 2024.
Presentation
Details:
Presenter: David Dodd, Chairman & CEO
Date/Time: February 26, 2024, 4:15 pm ET
Location: New York Marriott Marquis
Registration: BIO CEO & Investor Conference
GeoVax senior
management will also conduct one-on-one meetings during the conference. For
more information or to schedule a meeting, please visit the conference page here or contact
GeoVax Investor Relations.
GeoVax
Labs, Inc. is a clinical-stage biotechnology company developing novel therapies
and vaccines for solid tumor cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a novel
oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in
a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.
GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient populations.
Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a
primary vaccine for immunocompromised patients such as those suffering from
hematologic cancers and other patient populations for whom the current authorized
COVID-19 vaccines are insufficient, and as a booster vaccine in patients with
chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable COVID-19
booster among healthy patients who previously received the mRNA vaccines.
GeoVax has a leadership team who have driven significant value creation across
multiple life science companies over the past several decades. For more
information, visit our website: www.geovax.com.
